1. Home
  2. PATH vs ABVX Comparison

PATH vs ABVX Comparison

Compare PATH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UiPath Inc.

PATH

UiPath Inc.

HOLD

Current Price

$16.49

Market Cap

7.9B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$132.11

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PATH
ABVX
Founded
2005
2013
Country
United States
France
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
9.0B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PATH
ABVX
Price
$16.49
$132.11
Analyst Decision
Hold
Strong Buy
Analyst Count
15
12
Target Price
$15.50
$115.83
AVG Volume (30 Days)
27.5M
1.8M
Earning Date
12-03-2025
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$1,553,111,000.00
$6,231,374.00
Revenue This Year
$13.59
$6.80
Revenue Next Year
$9.61
N/A
P/E Ratio
$39.65
N/A
Revenue Growth
10.05
N/A
52 Week Low
$9.38
$4.77
52 Week High
$19.84
$148.83

Technical Indicators

Market Signals
Indicator
PATH
ABVX
Relative Strength Index (RSI) 52.33 56.07
Support Level $16.33 $139.42
Resistance Level $17.36 $147.00
Average True Range (ATR) 0.74 7.10
MACD -0.10 0.88
Stochastic Oscillator 25.83 59.52

Price Performance

Historical Comparison
PATH
ABVX

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: